Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor

Oncotarget

Volumn 8, Issue 41, 2017, Pages 69295-69302

  Robinson, Giles W ^a   Kaste, Sue C ^a   Chemaitilly, Wassim ^a   Bowers, Daniel C ^b   Laughton, Stephen ^c   Smith, Amy ^d   Gottardo, Nicholas G ^e   Partap, Sonia ^f   Bendel, Anne ^g   Wright, Karen D ^h   Orr, Brent A ^a   Warner, William C ⁱ   Onar Thomas, Arzu ^a   Gajjar, Amar ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Starship Children's Hospital   (United States)

^d ARNOLD PALMER HOSPITAL FOR CHILDREN   (United States)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f STANFORD UNIVERSITY   (United States)

^g CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Childhood toxicity; Hedgehog inhibitor; Medulloblastoma; Premature physeal fusion; Targeted therapy

Indexed keywords

GONADORELIN AGONIST; GROWTH HORMONE; PROTEIN PATCHED 1; VISMODEGIB;

ADJUVANT CHEMOTHERAPY; ARTICLE; BONE DEFECT; BONE DEFORMATION; BONE GROWTH; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CHILD; CLINICAL ARTICLE; CRANIOSPINAL IRRADIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EXPOSURE; DRUG RESPONSE; DRUG WITHDRAWAL; FAMILY HISTORY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GROWTH PLATE FUSION; HAND MALFORMATION; HEDGEHOG SIGNALING; HUMAN; KNEE RADIOGRAPHY; LEG PAIN; MALE; MEDULLOBLASTOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSCLEROSIS; PRECOCIOUS PUBERTY; PRESCHOOL CHILD; PROTEIN TARGETING; RADIATION EXPOSURE; RECURRENT DISEASE; RISK FACTOR; SCHOOL CHILD; SHORT STATURE; TREATMENT DURATION; TUMOR INVASION; WALKING DIFFICULTY;

EID: 85030227275     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.20619     Document Type: Article

References (23)

1. Ostrom QT, de Blank PM, Kruchko C, Petersen CM, Liao P, Finlay JL, Stearns DS, Wolff JE, Wolinsky Y, Letterio JJ, Barnholtz-Sloan JS. Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. Neuro Oncol. 2015; 16 Suppl 10:x1-x36. doi: 10.1093/neuonc/nou327.
2. Armstrong GT, Liu Q, Yasui Y, Huang S, Ness KK, Leisenring W, Hudson MM, Donaldson SS, King AA, Stovall M, Krull KR, Robison LL, Packer RJ. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009; 101:946-58. doi: 10.1093/jnci/djp148.
3. Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, Cho YJ, Koster J, Schouten-van Meeteren A, van Vuurden D, Clifford SC, Pietsch T, von Bueren AO, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012; 123:473-84. doi: 10.1007/s00401-012-0958-8.
4. Gajjar AJ, Robinson GW. Medulloblastoma-translating discoveries from the bench to the bedside. Nat Rev Clin Oncol. 2014; 11:714-22. doi: 10.1038/nrclinonc.2014.181.
5. Romer JT, Kimura H, Magdaleno S, Sasai K, Fuller C, Baines H, Connelly M, Stewart CF, Gould S, Rubin LL, Curran T. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell. 2004; 6:229-40. doi: 10.1016/j.ccr.2004.08.019.
6. Kimura H, Ng JM, Curran T. Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell. 2008; 13:249-60. doi: 10.1016/j.ccr.2008.01.027.
7. Gajjar A, Stewart CF, Ellison DW, Kaste S, Kun LE, Packer RJ, Goldman S, Chintagumpala M, Wallace D, Takebe N, Boyett JM, Gilbertson RJ, Curran T. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res. 2013; 19:6305-12. doi: 10.1158/1078-0432.CCR-13-1425.
8. Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, Packer RJ, Goldman S, Prados MD, Desjardins A, Chintagumpala M, Takebe N, Kaste SC, et al. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol. 2015. doi: 10.1200/JCO.2014.60.1591.
9. Lucas JT Jr, Wright KD. Vismodegib and Physeal Closure in a Pediatric Patient. Pediatr Blood Cancer. 2016; 63:2058. doi: 10.1002/pbc.25941.
10. Lum L, Beachy PA. The Hedgehog response network: sensors, switches, and routers. Science. 2004; 304:1755-9. doi: 10.1126/science.1098020.
11. Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Genes Dev. 2008; 22:2454-72. doi: 10.1101/gad.1693608.
12. Pak E, Segal RA. Hedgehog Signal Transduction: Key Players, Oncogenic Drivers, and Cancer Therapy. Dev Cell. 2016; 38:333-44. doi: 10.1016/j.devcel.2016.07.026.
13. Bangs F, Anderson KV. Primary Cilia and Mammalian Hedgehog Signaling. Cold Spring Harb Perspect Biol. 2017; 9. doi: 10.1101/cshperspect.a028175.
14. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012; 366:2171-9. doi: 10.1056/NEJMoa1113713.
15. Kieran MW, Chisholm J, Casanova M, Brandes AA, Aerts I, Bouffet E, Bailey S, Leary S, MacDonald TJ, Mechinaud F, Cohen KJ, Riccardi R, Mason W, et al. Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. Neuro Oncol. 2017. doi: 10.1093/neuonc/nox109.
16. Hellemans J, Coucke PJ, Giedion A, De Paepe A, Kramer P, Beemer F, Mortier GR. Homozygous mutations in IHH cause acrocapitofemoral dysplasia, an autosomal recessive disorder with cone-shaped epiphyses in hands and hips. Am J Hum Genet. 2003; 72:1040-6.
17. Laughton SJ, Merchant TE, Sklar CA, Kun LE, Fouladi M, Broniscer A, Morris EB, Sanders RP, Krasin MJ, Shelso J, Xiong Z, Wallace D, Gajjar A. Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. J Clin Oncol. 2008; 26:1112-8. doi: 10.1200/JCO.2008.13.5293.
18. Xu W, Janss A, Moshang T. Adult height and adult sitting height in childhood medulloblastoma survivors. J Clin Endocrinol Metab. 2003; 88:4677-81. doi: 10.1210/jc.2003-030619.
19. Bruzzi P, Predieri B, Corrias A, Marsciani A, Street ME, Rossidivita A, Paolucci P, Iughetti L. Final height and body mass index in adult survivors of childhood acute lymphoblastic leukemia treated without cranial radiotherapy: a retrospective longitudinal multicenter Italian study. BMC Pediatr. 2014; 14:236. doi: 10.1186/1471-2431-14-236.
20. Kronenberg HM. Developmental regulation of the growth plate. Nature. 2003; 423:332-6. doi: 10.1038/nature01657.
21. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM, Von Hoff DD, de Sauvage FJ, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009; 361:1173-8. doi: 10.1056/NEJMoa0902903.
22. Erivedge Prescribing Information. (South San Francisco, CA: Genentech USA Inc.). 2016.
23. Important Drug Warning Letter. (South San Francisco, CA: Genentech USA Inc.). 2016.